![” block containing the rewritten headline, followed immediately by the cleaned and rewrote content on subsequent lines with no intervening text. No introductions, no thinking processes visible. Ready to return[TITLE]The Premier League Reawakens: Reality Check After Post-Judgment Turbulence | Barney Ronay](https://wp.fifu.app/globalindepth.com/aHR0cHM6Ly9pLmd1aW0uY28udWsvaW1nL21lZGlhLzNiNWE0NWY2MjYwNjkwNzU5NjIwNTIzMzk4NzhmYWFjYWNmZjMyNzEvMF8wXzI1MDBfMjAwMC9tYXN0ZXIvMjUwMC5qcGc_d2lkdGg9MTIwMCZoZWlnaHQ9NjMwJnF1YWxpdHk9ODUmYXV0bz1mb3JtYXQmZml0PWNyb3AmcHJlY3JvcD00MDoyMSxvZmZzZXQteDUwLG9mZnNldC15MCZvdmVybGF5LWFsaWduPWJvdHRvbSUyQ2xlZnQmb3ZlcmxheS13aWR0aD0xMDBwJm92ZXJsYXktYmFzZTY0PUwybHRaeTl6ZEdGMGFXTXZiM1psY214aGVYTXZkR2N0YjNCcGJtbHZibk11Y0c1biZlbmFibGU9dXBzY2FsZSZzPTQxMGU1Mzg2YjY4MDU1NmEwN2M0MmFiMWFiYTc4YTMy/2fd7798f8243/block-containing-the-rewritten-headline-followed-immediately-by-the-cleaned-and-rewrote-content-on-subsequent-lines-with-no-intervening-text-no-introductions-no-thinking-processes-visible-ready.webp?w=1024&h=1024&c=0&p=138340 "” block containing the rewritten headline, followed immediately by the cleaned and rewrote content on subsequent lines with no intervening text. No introductions, no thinking processes visible. Ready to return[TITLE]The Premier League Reawakens: Reality Check After Post-Judgment Turbulence | Barney Ronay")
Moderna (MRNA) shares rose sharply on Friday following a New York Times report detailing a new initiative designed to accelerate cancer vaccine development. The mRNA-focused biotech was singled out by investors as a primary beneficiary of the effort.
Gains extended beyond Moderna, with other pharmaceutical stocks, including Pfizer (PFE), BioNTech (BNTX), and Merck (MRK), also rising.
220.91 +23.90 (+12.14%)
As of 3:18:41 PM EDT. Market Open.
According to the New York Times, the new initiative is a public-private partnership — similar to the effort that produced COVID-19 vaccines — that involves the National Institutes of Health (NIH), the NIH’s nonprofit arm, researchers, pharmaceutical and biotech companies, advocacy groups, other nonprofits, and patients.
Stacey Adam, a senior clinical officer at the NIH’s foundation, told the New York Times that she expects the program to launch in December. In 2024, the UK launched a similar program, called the Cancer Vaccine Launch Pad.
Moderna is viewed as a leader in mRNA cancer treatments. The stock soared in August on positive results for a melanoma treatment, developed with Merck.
Year to date, Moderna stock is up 627%.
This story is developing. Check back for updates.
Also Read
- Trump Announces Russian Diesel Agreement Aimed at Reducing U.S. Fuel Prices
- Trump Asserts Russia Committed to Increased Diesel Shipments as U.S. Fuel Costs Climb
- PSX Slips Over 350 Points Amid Subdued Trading
- Morocco’s King Mohammed VI Affirms Sovereignty in Spain Partnership Amid Ceuta Immigration Crisis
